funding

Eli Lilly supports Alto Neuroscience in $45m Series C round
Eli Lilly supports Alto Neuroscience in $45m Series C round
Clinical Trials Arena
Eli Lilly
Alto Neuroscience
funding
psychiatric diesase
Flag link:
Nouscom raises $72m in Series C financing round to develop cancer vaccines
Nouscom raises $72m in Series C financing round to develop cancer vaccines
Clinical Trials Arena
Nouscom
funding
cancer
cancer vaccines
Flag link:
Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Fierce Biotech
VectorY Therapeutics
funding
ALS
Merck
Flag link:
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
BioSpace
ViaNautis Bio
Eli Lilly
genetic nanomedicine
UCB Pharma
funding
Flag link:
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
BioPharma Dive
OrsoBio
Eli Lilly
funding
obesity
diabetes
Flag link:
SkyCell raises $57M at a $600M valuation to build smart containers for pharmaceutical transport
SkyCell raises $57M at a $600M valuation to build smart containers for pharmaceutical transport
TechCrunch
SkyCell
funding
distrbution
logistics
Flag link:
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
BioPharma Dive
Maplight Therapeutics
funding
schizophrenia
Flag link:
Abingworth raises $356M to invest in late-stage drug development
Abingworth raises $356M to invest in late-stage drug development
BioPharma Dive
venture capital
funding
Abingworth
drug development
Flag link:
Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024
Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024
BioPharma Dive
biotech
funding
IPOs
Flag link:
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
BioSpace
Triveni Bio
funding
atopic dermatitis
Flag link:
'By hook or by crook': BIO CEO urges biotechs to be flexible on funding to survive tough times
'By hook or by crook': BIO CEO urges biotechs to be flexible on funding to survive tough times
Fierce Biotech
BIO
biotech
funding
Inflation Reduction Act
Flag link:
Aiolos Bio launches with ex-Gyroscope CEO at the helm, nearly $250M to advance severe asthma med
Aiolos Bio launches with ex-Gyroscope CEO at the helm, nearly $250M to advance severe asthma med
Fierce Biotech
Aiolos Bio
funding
asthma
severe asthma
Flag link:
‘Project NextGen’ picks new mRNA, intranasal COVID vaccines for funding
‘Project NextGen’ picks new mRNA, intranasal COVID vaccines for funding
BioPharma Dive
Project NextGen
MRNA
COVID-19
vaccines
funding
Gritstone Bio
Codagenix
CastleVax
Flag link:
5 financial challenges facing the medtech sector
5 financial challenges facing the medtech sector
Medtech Dive
Medtech
revenue
M&A
spinoffs
funding
IPOs
Flag link:
After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma
After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma
Fierce Biotech
biotech
funding
venture capital
Flag link:
Evozyne raises $81m to leverage AI for drug discovery
Evozyne raises $81m to leverage AI for drug discovery
Biopharma Reporter
Evozyne
funding
drug discovery
artificial intelligence
Flag link:
Amicus Therapeutics secures $430M from Blackstone in financing agreement
Amicus Therapeutics secures $430M from Blackstone in financing agreement
Medical Marketing and Media
Amicus Therapeutics
Blackstone
funding
Flag link:
'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023
'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023
Fierce Biotech
Europe
funding
venture capital
Forbion
BioGeneration Ventures
Medicxi
Flag link:
Harbinger Health foreshadows launch of blood-based cancer screening platform with $140M VC round
Harbinger Health foreshadows launch of blood-based cancer screening platform with $140M VC round
Fierce Biotech
Harbinger Health
Medtech
diagnostics
cancer
funding
liquid biopsy
Flag link:
Vaccinex Announces Pricing of $9.6 Million Public Offering
Vaccinex Announces Pricing of $9.6 Million Public Offering
BioSpace
Vaccinex
funding
Flag link:

Pages